熱門資訊> 正文
Alvotech因积极数据支持武田Entyvio的生物仿制药而走高
2026-02-05 21:15
- Alvotech (ALVO) shares spiked ~3% in the premarket on Thursday after the Luxembourg-based biotech succeeded in a study designed to evaluate AVT80, its proposed biosimilar to Entyvio, a bowel disease therapy marketed by Takeda (TAK).
- Citing topline data, Alvotech (ALVO) said that its pharmacokinetic (PK) study for AVT80 met its primary endpoints. The trial named AVT80-GL-P01 was designed to compare single 108 mg/0.68 mL subcutaneous (SC) injections of AVT80 and Entyvio in healthy adults.
- According to the company, Entyvio—approved for ulcerative colitis and Crohn’s disease—generated $6.4B in global net revenue last year.
- Alvotech (ALVO) noted that, based on regulatory feedback, AVT80-GL-P01 meets expectations to demonstrate PK similarity of its Entyvio versions, AVT80 and AVT16, targeted at subcutaneous and intravenous administrations.
More on Alvotech, Takeda Pharmaceutical
- Takeda Tests New Highs, But Struggles To Find Entyvio Successor
- Takeda Pharmaceutical Company Limited (TAK) Q3 FY2025 Earnings Call Transcript
- Alvotech: Why FDA Delays Don't Break The Bull Case
- Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar
- Takeda Pharmaceutical Non-GAAP EPS of ¥428.00, revenue of ¥3411.2B; updates FY26 outlook
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
